cfMeDIP-seq for NEPC Detection via DNA Methylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neuroendocrine prostate cancer (NEPC) are inadequate due to lack of consensus in pathological criteria and intra-patient tumor heterogeneity, leading to delayed or missed diagnoses, and existing genetic markers are not specific enough to detect NEPC effectively.
Innovation Solution
Identification of differentially methylated regions (DMRs) in the genome using cell-free DNA immunoprecipitation sequencing (cfMeDIP-seq) to differentiate between NEPC and prostate adenocarcinoma (PRAD) with high accuracy, enabling early detection and tailored treatment options.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If tissue biopsy is performed for pathologic tumor analysis, then diagnostic information can be obtained, but the diagnosis may be delayed or missed due to intra-patient tumor heterogeneity and lack of consensus pathological criteria
Solution Approach 1:
The patent uses liquid biopsy as an intermediary diagnostic method that analyzes circulating tumor cells and tumor DNA in bodily fluids, providing a representative sample of the entire tumor burden without the sampling limitations of tissue biopsy. This intermediary approach resolves the contradiction by enabling accurate NEPC detection while avoiding the timing delays associated with traditional biopsy methods
Solution Approach 2:
The patent changes the diagnostic parameter from histological examination of tissue samples to molecular analysis of circulating tumor DNA methylation patterns and gene expressions. This parameter change enables detection of NEPC-specific molecular signatures that are present throughout the tumor burden, resolving the contradiction between diagnostic accuracy and timing by providing comprehensive tumor information from liquid samples
2Measurement precision
If genetic alterations such as RB1 and TP53 mutations are used to detect NEPC, then some detection capability is provided, but the markers are not specific enough as these alterations are present in more than one-third of castration-resistant PRAD tumors
Solution Approach 1:
The patent applies local quality by identifying NEPC-specific molecular signatures with distinct patterns of gene expression and DNA methylation that are localized to the neuroendocrine phenotype. Rather than relying on general genetic alterations present in multiple cancer types, the method detects specific epigenetic marks and transcriptional programs that are uniquely characteristic of NEPC transformation, thereby resolving the specificity problem
Solution Approach 2:
The patent segments the diagnostic approach into multiple independent molecular assays that detect different aspects of NEPC biology, including DNA methylation patterns at specific genomic loci, gene expression profiles of neuroendocrine markers, and chromosomal instability patterns. This segmentation allows the method to distinguish NEPC from PRAD by requiring a combination of specific molecular features rather than relying on a single non-specific genetic alteration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a non-invasive, clinically actionable approach for detecting NEPC with high sensitivity and specificity, allowing for timely intervention and improved patient outcomes by distinguishing between NEPC and PRAD through distinct methylation profiles.
Implementation Method 1
DNA methylation profiles of NEPC and PRAD tumors demonstrate striking differences
Implementation Method 2
cell-free DNA immunoprecipitation sequencing (cfMeDIP-seq)
Data Source
AI summary
Methods and compositions are provided for detecting the presence of neuroendocrine prostate cancer in a subject by analyzing DNA methylomes.